3SBio Inc. has announced the signing of an exclusive licensing agreement with Pfizer Inc. for the development of a PD-1/VEGF bispecific antibody known as SSGJ-707. This agreement is a strategic move aimed at bringing the innovative treatment to patients worldwide. Additionally, 3SBio revealed that there is a possibility of Pfizer subscribing to a number of new shares of the company, although no binding agreement has been reached on this potential subscription. The company advises shareholders and potential investors to exercise caution when dealing with its shares. The agreement also includes an option for Pfizer to commercialize the licensed product in mainland China, pending regulatory approvals. Morgan Stanley Asia Limited and Han Kun Law Offices are advising 3SBio on this transaction.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。